Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan

References

• Global Initiative for Chronic Obstructive Lung DiseaseGlobal strategy for the diagnosis, management, and prevention of COPD2014 Available from: http://www.goldcopd.org/Accessed October 20, 2014
   Google Scholar
• VinckenWAumannJChenHHenleyMMcBryanDGoyalPEfficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 studyInt J Chron Obstruct Pulmon Dis2014921522824596459
   PubMed Web of Science ®Google Scholar
• ChungVCMaPHHuiDSTamWWTangJLIndacaterol for chronic obstructive pulmonary disease: systematic review and meta-analysisPLoS One20138e7078423967106
   PubMed Web of Science ®Google Scholar
• DonohueJFFogartyCLötvallJINHANCE Study InvestigatorsOnce-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropiumAm J Respir Crit Care Med201018215516220463178
   PubMed Web of Science ®Google Scholar
• D’UrzoAFergusonGTvan NoordJAEfficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trialRespir Res20111215622151296
   PubMed Web of Science ®Google Scholar
• RossiAPoleseGIndacaterol: a comprehensive reviewInt J Chron Obstruct Pulmon Dis2013835336323922496
   PubMed Web of Science ®Google Scholar
• SteiropoulosPArchontogeorgisKNenaEBourosDNew developments in the management of COPD: clinical utility of indacaterol 75 μgInt J Chron Obstruct Pulmon Dis201491724353414
   PubMed Web of Science ®Google Scholar
• ChapmanKRBeehKMBeierJA blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 studyBMC Pulm Med201414424438744
   PubMed Web of Science ®Google Scholar
• BuhlRBanerjiDProfile of glycopyrronium for once-daily treatment of moderate-to-severe COPDInt J Chron Obstruct Pulmon Dis2012772974123118536
   PubMed Web of Science ®Google Scholar
• UlrikCSOnce-daily glycopyrronium bromide, a long-acting muscarinic antagonist, for chronic obstructive pulmonary disease: a systematic review of clinical benefitInt J Chron Obstruct Pulmon Dis2012767367823055716
   PubMed Web of Science ®Google Scholar
• ComptonCMcBryanDBucchioniEPatalanoFThe Novartis view on emerging drugs and novel targets for the treatment of chronic obstructive pulmonary diseasePulm Pharmacol Ther20132656257323748050
   PubMed Web of Science ®Google Scholar
• FramptonJEQVA149 (indacaterol/glycopyrronium fixed-dose combination): a review of its use in patients with chronic obstructive pulmonary diseaseDrugs20147446548824604791
   PubMed Web of Science ®Google Scholar
• SchachterENIndacaterol/glycopyrronium bromide fixed-dose combination for the treatment of COPDDrugs Today (Barc)20134943744623914352
   PubMed Web of Science ®Google Scholar
• ScottLJHairPUmeclidinium/Vilanterol: first global approvalDrugs20147438939524532124
   PubMed Web of Science ®Google Scholar
• NelsonHSAdvair: combination treatment with fluticasone propionate/salmeterol in the treatment of asthmaJ Allergy Clin Immunol200110739841611174215
   PubMed Web of Science ®Google Scholar
• KunaPKuprysISymbicort Turbuhaler: a new concept in asthma managementInt J Clin Pract20025679780312510955
   PubMed Web of Science ®Google Scholar
• HonigPKRecent trends and success factors in reducing the lag time to approval of new drugs in JapanClin Pharmacol Ther20149546746924747231
   PubMed Web of Science ®Google Scholar
• UenoTAsahinaYTanakaAYamadaHNakamuraMUyamaYSignificant differences in drug lag in clinical development among various strategies used for regulatory submissions in JapanClin Pharmacol Ther20149553354124213186
   PubMed Web of Science ®Google Scholar
• Van de MaeleBFabbriLMMartinCHortonRDolkerMOverendTCardiovascular safety of QVA149, a combination of Indacaterol and NVA237, in COPD patientsCOPD20107641842721166630
   PubMedGoogle Scholar
• van NoordJABuhlRLaforceCQVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary diseaseThorax2010651086109120978028
   PubMed Web of Science ®Google Scholar
• DahlRChapmanKRRudolfMSafety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN studyRespir Med20131071558156723867808
   PubMed Web of Science ®Google Scholar
• BeehKMKornSBeierJEffect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT studyRespir Med201410858459224534204
   PubMed Web of Science ®Google Scholar
• WedzichaJADecramerMFickerJHAnalysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group studyLancet Respir Med2013119920924429126
   PubMed Web of Science ®Google Scholar
• BatemanEDFergusonGTBarnesNDual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE studyEur Respir J2013421484149423722616
   PubMed Web of Science ®Google Scholar
• MahlerDADecramerMD’UrzoADual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE studyEur Respir J2014431599160924176997
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.govLong term safety and tolerability of QVA149 versus tiotropium in Japanese patients with chronic obstructive pulmonary disease (COPD) (ARISE) Available from: http://www.clinicaltrials.gov/ct2/show/NCT1285492?term=%28ARISE%29&rank=4Accessed October 20, 2014
   Google Scholar
• ClinicalTrials.govComparison of long-term safety of the combination product QVA149A against placebo and standard of care treatment in chronic obstructive pulmonary disease patients with moderate to severe airflow limitation (RADIATE) Available from: www.clinicaltrials.gov/ct2/show/NCT1610037?term=GLISTEN&rank=1Accessed October 20, 2014
   Google Scholar
• VogelmeierCFBatemanEDPallanteJEfficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group studyLancet Respir Med20131516024321804
   PubMed Web of Science ®Google Scholar
• ZhongNWangXZhouNEfficacy and safety of once-daily QVA149 compared with twice-daily salmeterol/fluticasone combination (SFC) in patients with COPD: the LANTERN studyEuropean Respiratory SocietySeptember 8, 2014 Abstract 700090; Session 281
   Google Scholar
• ClinicalTrial.govA 52-week treatment, multi-center, randomized, double-blind, double dummy, parallel-group, active controlled study to compare the effect of QVA149 (indacaterol maleate/glycopyrronium bromide) with salmeterol/futicasone on the rate of exacerbations in subjects with moderate to very severe COPD (FLAME) Available at: http://clinicaltrials.gov/ct2/show/NCT1782326?term=COPD+novartis+52&rank=2Accessed October 20, 2014
   Google Scholar
• DahlRJadayelDAlagappanVKChenHBanerjiDEfficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON studyInt J Chron Obstruct Pulmon Dis2013850150824159259
   PubMed Web of Science ®Google Scholar
• KornSGebnerCSchurmannWOnce-daily QVA149 improves dyspnea, quality of life and reduces the rate of exacerbations compared to tiotropium plus formoterol in COPD patients: the QUANTIFY studyMay 21, 2014 ATS abstract # 50965(Publication number A5982)Thematic Poster Session D44
   Google Scholar
• Deliberation Result ReportJapan: Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare2013 Available from: http://www.info.pmda.go.jp/shinyaku/P201300135/300242000_22500AMX01815_A100_5.pdf#search=‘%E5%8C%BB%E8%96%AC%E9%A3%9F%E5%93%81%E5%B1%80%E5%AF%A9%E6%9F%BB%E7%AE%A1%E7%90%86%E8%AA%B2+%E3%82%A6%E3%83%AB%E3%83%86%E3%82%A3%E3%83%96%E3%83%AD. JapaneseAccessed October 20, 2014
   Google Scholar
• TashkinDPCelliBSennSUPLIFT Study InvestigatorsA 4-year trial of tiotropium in chronic obstructive pulmonary diseaseN Engl J Med20083591543155418836213
   PubMed Web of Science ®Google Scholar
• GeßnerCSchurmannWForsterKOnce-daily QVA149 demonstrates superior improvements in lung function compared to tiotropium plus formoterol: the QUANTIFY studyMay 21, 2014 ATS abstract # 50961(Publication Number A5983)Thematic Poster Session D44
   Google Scholar
• Fourth Edition of the Japanese Respiratory Society COPD Guideline for Diagnosis and TreatmentTokyo, JapanThe Japanese Respiratory Society2013 Japanese
   Google Scholar
• SpencerSCalverleyPMBurgePSJonesPWImpact of preventing exacerbations on deterioration of health status in COPDEur Respir J20042369870215176682
   PubMed Web of Science ®Google Scholar
• SuzukiMMakitaHItoYMNagaiKKonnoSNishimuraMHokkaido COPD Cohort Study InvestigatorsClinical features and determinants of COPD exacerbation in the Hokkaido COPD cohort studyEur Respir J2014431289129724232696
   PubMed Web of Science ®Google Scholar
• PapaiwannouAZarogoulidisPPorpodisKAsthma-chronic obstructive pulmonary disease overlap syndrome (ACOS): current literature reviewJ Thorac Dis20146S146S15124672688
   PubMed Web of Science ®Google Scholar
• Berrington de GonzálezADarbySRisk of cancer from diagnostic X-rays: estimates for the UK and 14 other countriesLancet200436334535115070562
   PubMed Web of Science ®Google Scholar
• IchinoseMAizawaHIshizakaAChronic obstructive pulmonary disease (COPD) burden in Japan – confronting COPD Japan surveyNihon Kokyuki Gakkai Zasshi200745927935 Japanese18186237
   PubMedGoogle Scholar
• IshiiTTeramotoSMiyashitaAChronic obstructive pulmonary disease (COPD) in the elderly: analysis from questionnaire about attitudes to the COPD guideline of the Japanese Respiratory Society and actual therapy for COPD used by physiciansNihon Kokyuki Gakkai Zasshi200240113122 Japanese11974865
   PubMedGoogle Scholar
• SuissaSBarnesPJInhaled corticosteroids in COPD: the case againstEur Respir J200934131619567599
   PubMed Web of Science ®Google Scholar
• CalverleyPMAndersonJACelliBTORCH investigatorsSalmeterol and fluticasone propionate and survival in chronic obstructive pulmonary diseaseN Engl J Med200735677578917314337
   PubMed Web of Science ®Google Scholar
• AaronSDVandemheenKLFergussonDTiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trialAnn Intern Med200714654555517310045
   PubMed Web of Science ®Google Scholar
• WedzichaJACalverleyPMSeemungalTAHaganGAnsariZStockleyRAINSPIRE InvestigatorsThe prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromideAm J Respir Crit Care Med2008177192617916806
   PubMed Web of Science ®Google Scholar
• SuissaSErnstPVandemheenKLAaronSDMethodological issues in therapeutic trials of COPDEur Respir J20083192793318216056
   PubMed Web of Science ®Google Scholar
• ShibuyaKHashimotoHIkegamiNFuture of Japan’s system of good health at low cost with equity: beyond universal coverageLancet20113781265127321885100
   PubMed Web of Science ®Google Scholar
• BeanJRNational healthcare spending in the U.S. and Japan: national economic policy and implications for neurosurgeryNeurol Med Chir (Tokyo)200545182415699616
   PubMed Web of Science ®Google Scholar
• MiyataHMotomuraNKondoJTakamotoSHasegawaTImproving the quality of healthcare in Japan: a systematic review of procedural volume and outcome literatureBiosci Trends20071818920103873
   PubMed Web of Science ®Google Scholar
• YokokuraYEfforts of the Japan medical association to support physicians to provide quality healthcareJapan Med Assoc J201255205207
   Google Scholar